Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Blood (2025) 146 (Supplement 1): 247.

https://doi.org/10.1182/blood-2025-247

Published: 2025

Journal Articles

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V. Kostopoulos, Romanos Sklavenitis-Pistofidis, Febe Smits, Carmen Roncal, Michelle Aranha, David Zihala, Michaela Machu, Nikolaos Tsakirakis, Panagiotis Bakouros, Ourania Tsitsilonis, Eirini Solia, Cristina Moreno, Catarina Maia, Esperanza Martin-Sanchez, José J. Perez, Cristina Encinas, Rafael Rios Tamayo, Albert Oriol, María-Jesús Blanchard, Felipe de Arriba, Esther González García, Sunil Lakhwani, Anna Sureda Balarí, Valentin Cabanas Perianes, Fernando Escalante Barrigón, Estrella Carrillo-Cruz, Albert Pérez-Montaña, Enrique Ocio, Joan Bargay, Alberto Orfao, Tomas Jelinek, Irene Ghobrial, Tuna Mutis, Sonja Zweegman, Evangelos Terpos, Efstathios Kastritis, Joaquin Martinez-Lopez, Juan-Jose Lahuerta Palacios, Carlos Fernandez de Larrea, Laura Rosiñol, Joan Batista Blade Creixenti, Paula Rodriguez-Otero, María-Victoria Mateos, Jesus San-Miguel, Maria Teresa Cedena Romero, Noemí Puig, Bruno Paiva

Blood (2025) 146 (Supplement 1): 365.

https://doi.org/10.1182/blood-2025-365

Published: 2025

Journal Articles

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

Beatriz Chiclana-Rodríguez, Marta García Culebras, Patricia Alcalde-Mellado, Nancy Rodriguez-Torres, Lucía Mezquita Romero, Juan Luis Reguera, Javier Camuña Correa, Estrella Carrillo-Cruz, Marta Reinoso -Segura, Eusebio Martín Chacón, Laura Pérez Ortega, Jose Francisco Falantes, Cristina Blazquez Go I, Francisco Manuel Martin-Dominguez, Maria Eva Mingot, Virginia Escamilla Gomez, José Antonio Pérez-Simón

Blood (2025) 146 (Supplement 1): 4061.

https://doi.org/10.1182/blood-2025-4061

Published: 2025

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blood (2024) 144 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2024-205453

Published: 2024

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Santiago Montes-Moreno, Sr., Aitana Avendaño, Sonia Gonzalez De Villambrosia, Laura Rodriguez-Merino, Jordi Morata, Raul Tonda, Estrella Carrillo-Cruz, Carlos Grande, Jose Maria Roncero, Jaime Perez De Oteyza, Concepcion Nicolas, Beatriz Rey Búa, Pau Abrisqueta, Antonio Gutierrez, Angel Ramirez, Alejandro Martin Garcia-Sancho, Eva Maria Gonzalez Barca

Blood (2023) 142 (Supplement 1): 6092.

https://doi.org/10.1182/blood-2023-179150

Published: 2023

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Blood (2022) 140 (Supplement 1): 246–248.

https://doi.org/10.1182/blood-2022-165402

Published: 2022

Journal Articles

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

Blood (2022) 140 (Supplement 1): 3438–3440.

https://doi.org/10.1182/blood-2022-160136

Published: 2022

Journal Articles

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Jose F. Falantes, Francisco J. Márquez-Malaver, Estrella Carrillo-Cruz, Rosario M Morales-Camacho, Concepción Prats-Martín, Teresa Caballero, Eduardo Rodriguez Arbolí, Ildefonso Espigado, Jose A. Perez-Simon

Blood (2022) 140 (Supplement 1): 6920–6922.

https://doi.org/10.1182/blood-2022-169372

Published: 2022

Journal Articles

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2101–2103.

https://doi.org/10.1182/blood-2022-167247

Published: 2022

Journal Articles

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Blood (2021) 138 (Supplement 1): 466.

https://doi.org/10.1182/blood-2021-146798

Published: 2021

Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140934

Published: 2020

Journal Articles

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Nerea Martinez, PhD, Sonia González de Villambrosia, MD, Ainara Pereña, Raul Tonda, Sergi Beltran, PhD, Marta Gut, PhD, Estrella Carrillo-Cruz, MD, Carlos Grande, MD, Alejandro Martín, MD, Concepcion Nicolas, MD, Jose Maria Roncero, MD, Maria J. Rodriguez-Salazar, MD, Jaime Perez De Oteyza, MDPhD, Eulogio Conde, MD PhD, Eva Gonzalez-Barca, Santiago Montes-Moreno, MD PhD

Blood (2018) 132 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2018-99-113757

Published: 2018

Journal Articles

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Blood (2017) 130 (Supplement 1): 2008.

https://doi.org/10.1182/blood.V130.Suppl_1.2008.2008

Published: 2017

Journal Articles

Influence of VDR Polymorphisms on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) within the Alovita Trial.

Estrella Carrillo-Cruz, MD, Teresa Caballero-Velázquez, MD PhD, Isabel Montero, MD, Fermin Sanchez-Guijo, MD PhD, Miguel Alcoceba, PhD, Christelle Marie Ferra I Coll, David Valcarcel, Rocio Parody, MD, Lucia Lopez Corral, Oriana López-Godino, Marian Cuesta, Francisco Marquez, Teresa Ramos, José Raúl Garcia-Lozano, José A. Pérez-Simón

Blood (2017) 130 (Supplement 1): 3251.

https://doi.org/10.1182/blood.V130.Suppl_1.3251.3251

Published: 2017

Journal Articles

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Blood (2016) 128 (22): 4201.

https://doi.org/10.1182/blood.V128.22.4201.4201

Published: 2016

Journal Articles

Role of PET/CT Assesment before Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma Patients

Fátima de la Cruz Vicente, MD, Maria Angeles Domiunguez Muñoz, MD, Estrella Carrillo Cruz, MD, José Francisco Márquez Malaver, Rocio Parody Porras, MD, Jose Francisco Falantes González, MD, Cristina Calderón Cabrera, MD, Olga Pérez López, MD, María Solé Rodríguez, MD, Jose González Campos, MD, María Isabel Montero Cuadrado, MD, María Luz Martino Galiana, MD, Jose Antonio Pérez-Simón, PhD, Ildefonso Espigado, PhD

Blood (2014) 124 (21): 3977.

https://doi.org/10.1182/blood.V124.21.3977.3977

Published: 2014

Journal Articles

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Fátima de la Cruz Vicente, Estrella Carrillo Cruz, María Solé Rodríguez, Ana Marín Niebla, Eduardo Ríos Herranz, María Luz Martino Galiana, Jose Falantes González, Isabel Montero Cuadrado, Jose González Campos, Ildefonso Espigado Tocino, Jose A Pérez-Simón

Blood (2013) 122 (21): 5087.

https://doi.org/10.1182/blood.V122.21.5087.5087

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study

Immune biomarkers of increased risk of infection in multiple myeloma (MM)

Comparative analysis of toxicity and efficacy of melphalan at doses of 140 mg/m2 VS. 200 mg/m2 as a conditioning regimen prior to autologous stem cell transplantation.

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Genetic Subtyping Using Whole Exome Sequencing across Large B Cell Lymphoma Entities in a Series of 109 DLBCL and Plasmablastic Lymphoma Cases

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3 , IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease

Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Cell Free Tumor DNA for DLBCL Genotyping in a Phase II Randomized Trial Comparing Standard RCHOP Versus Brcap As First Line Treatment in Patients with Poor IPI DLBCL

Efficacy of Autologous Stem Cell Transplantation in First Complete Remission in Patients with Peripheral T-Cell Lymphoma: A Multicenter Geltamo/FIL Study

Influence of VDR Polymorphisms on the Outcome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) within the Alovita Trial.

Phase 2 Randomized Trial Comparing Standard RCHOP Versus Brcap (bortezomib, rituximab, cyclophosphamide, adriamycin and prednisone) As First Line Treatment in Young Patients with High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). a Study from Spanish Group Geltamo

Role of PET/CT Assesment before Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma Patients

Fludarabine, Cyclophosphamide and Rituximab As First Line Treatment In Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only